Levels of beta amyloid, a protein linked with Alzheimer's, increased in the blood of patients...

Levels of beta amyloid, a protein linked with Alzheimer's, increased in the blood of patients treated with Eli Lilly's (NYSE:LLY) solanezumab in two Phase III trials, suggesting that the protein was removed from the brain as intended. As already disclosed, Solanezumab seems to be able to slow Alzheimer's progression in patients with mild symptoms, so the latest finding provides validity to the belief that amyloid is a cause.